<DOC>
	<DOCNO>NCT01797536</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics ( PK ) profile elbasvir ( MK-8742 ) single dose participant mild , moderate , severe hepatic insufficiency compare healthy control .</brief_summary>
	<brief_title>The Influence Hepatic Insufficiency Pharmacokinetics Elbasvir ( MK-8742 ) ( MK-8742-009 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<criteria>Body mass index ( BMI ) 19 40 kg/m^2 , inclusive In good health base medical history , physical examination , vital sign , laboratory safety test No clinically significant abnormality electrocardiogram ( ECG ) For participant hepatic insufficiency , diagnosis chronic ( &gt; 6 month ) , stable ( acute episode illness within previous 2 month due deterioration hepatic function ) hepatic insufficiency feature cirrhosis due cause For participant hepatic insufficiency , score ChildPugh scale must range 5 6 mild hepatic insufficiency , 7 9 moderate hepatic insufficiency , 10 15 severe hepatic insufficiency Females childbearing potential must either sexually inactive ( abstinent ) 14 day study drug administration throughout study use acceptable method birth control Females nonchildbearing potential must undergo sterilization procedure least 6 month Study Day 1 Nonvasectomized male must agree use condom spermicide abstain sexual intercourse study 3 month study drug administration Ability swallow multiple capsule Previously enrol study Mentally legally incapacitate , significant emotional problem time screen expect conduct study , history clinically significant psychiatric disorder last 5 year History presence significant cardiovascular , pulmonary , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurological disease History illness might confound result study pose additional risk participant participate study For participant hepatic insufficiency , estimate creatinine clearance ( CrCl ) â‰¤30 mL/min base CockcroftGault equation screen History presence drug abuse within past 2 year For healthy participant , history alcoholism within past 2 year Females pregnant lactate Positive result urine drug screen screen checkin Positive result screen history human immunodeficiency virus ( HIV ) untreated hepatitis C virus ( HCV ) ; HCV ribonucleic acid ( RNA ) negative participant document cure follow antiHCV treatment eligible For healthy participant , positive result screen hepatitis B surface antigen ( HBsAg ) Use drug substance know strong inhibitor cytochrome P450 3A4 ( CYP3A4 ) enzymes and/or Pglycoprotein ( Pgp ) inhibitor organic anion transport peptide 1B ( OATP1B ) within 14 day 5times halflife product ( healthy participant ) discontinue least 14 day 5 time halflife product ( hepatic insufficiency participant ) study drug administration throughout study Use drug substance know strong inducer CYP3A4 enzymes and/or Pgp , include StJohn 's Wort rifampin , within 28 day 5 time halflife product study drug administration Currently use medication substance discontinue maintain steady dose regimen least 14 day study drug administration throughout study For healthy participant , special diet within 28 day study drug administration Blood donation &gt; 500 mL significant blood loss within 56 day study drug administration Plasma donation within 7 day study drug administration Participation another clinical study within 28 day study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>